The Real Reasons Your Weight Loss Has Stalled
Why Am I Not Losing Weight on Wegovy: Understanding Treatment Plateaus
When patients ask "why am I not losing weight on Wegovy", the answer often lies in dose progression or medication switching history. If you've recently transitioned from Mounjaro (tirzepatide) to Wegovy (semaglutide), your body may need time to adjust to the different GLP-1 receptor mechanism. Mounjaro targets both GLP-1 and GIP receptors, whilst Wegovy focuses specifically on GLP-1 pathways, which can create temporary plateaus during the switch period.
Many patients find their weight loss resumes once they reach Wegovy's maintenance dose of 2.4mg, typically achieved by week 17 of treatment. The mandatory dose escalation schedule (0.25mg→0.5mg→1mg→1.7mg→2.4mg) ensures your body adapts gradually, but this process can feel slow if you were previously on higher Mounjaro doses. Our clinical team at EverydayMeds can review your current regimen and suggest timing adjustments to optimise your results whilst maintaining the prescription-only medicine's safety profile.
Switch and Save: Cost-Effective Wegovy Pricing Solutions
Switching to EverydayMeds for your Wegovy supply can address both efficacy concerns and budget pressures simultaneously. Our single pen prices start at £79.99 for the 0.25mg starter dose, with the maintenance 2.4mg dose priced at £209.99 – often £50-150 less than high street alternatives. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for continued savings on their prescription-only medicine.
Our Getting Started bundles make dose transitions seamless and cost-effective. The Intro Trio (0.25mg, 0.5mg & 1mg) costs £299.99, providing your first 12 weeks of treatment in one convenient order. For patients maintaining stable doses, our Consistency bundles offer two pens of the same strength – the Consistency 2.4mg bundle provides two maintenance pens for £419.99. These bundles eliminate the stress of reordering whilst ensuring continuous treatment during your weight management journey.
Why Am I Not Losing Weight on Wegovy: Clinical Evidence and Expectations
In clinical trials, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved an average of ~clinically studied weight loss at 68 weeks compared to ~2.4% with placebo (Wilding et al., NEJM, 2021). However, these results represent averages across diverse patient populations, and individual responses vary significantly. The STEP 5 trial demonstrated that ~clinically studied weight loss can be sustained at 2 years, but plateau periods are normal and expected during long-term treatment.
If you're asking "why am I not losing weight on Wegovy", consider that the medication works by reducing appetite and promoting satiety rather than directly burning fat. This mechanism requires consistent adherence to dietary modifications and physical activity increases to achieve optimal results. Some patients experience renewed weight loss after switching from other GLP-1 medications due to improved tolerance, better injection timing, or enhanced dietary compliance with semaglutide's appetite effects.
How Wegovy's GLP-1 Mechanism Addresses Weight Plateaus
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate blood sugar and appetite. Unlike Mounjaro's dual GLP-1/GIP action, Wegovy's focused GLP-1 pathway may provide more consistent appetite suppression for some patients. The medication works primarily on brain appetite centres, reducing food cravings and promoting feelings of fullness after smaller meals. This mechanism explains why patients switching from other medications sometimes experience renewed weight loss – the different receptor targeting can "reset" appetite responses. When administered via the convenient FlexTouch pen system, semaglutide maintains steady blood levels throughout the week, providing consistent appetite control that supports long-term weight management goals.
Streamlined Ordering Process for Medication Switches
Switching to EverydayMeds for your Wegovy prescription takes just minutes through our online clinical assessment system. Our 3-minute questionnaire captures your current medication history, including any previous Mounjaro or Ozempic use, enabling our prescribers to recommend appropriate starting doses for your switch. Standard prescriber review takes 3 working days, with express 24-hour options available for urgent medication transitions. Once approved, your prescription-only medicine ships via next-day delivery using temperature-controlled packaging to maintain the 2-8°C storage requirements. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance throughout the ordering and dispensing process, giving you confidence in your medication quality and legal supply chain.
Storage and Practical Advantages During Medication Transitions
Wegovy's storage flexibility makes it ideal for patients switching from temperature-sensitive alternatives like Mounjaro. Whilst both medications require refrigeration (2-8°C) before first use, Wegovy can remain at room temperature below 30°C for up to 6 weeks once removed from the fridge – compared to Mounjaro's 21-day limit. This extended stability is particularly valuable during travel or if refrigeration becomes temporarily unavailable. The FlexTouch pen system requires no mixing or preparation, simply attach a new needle and inject subcutaneously once weekly. The mandatory dose escalation schedule (starting at 0.25mg for weeks 1-4) helps minimise gastrointestinal side effects that sometimes cause treatment discontinuation with other GLP-1 medications, ensuring better long-term adherence to your weight management regimen.
Why Am I Not Losing Weight on Wegovy: Switching Strategies That Work
Many patients asking "why am I not losing weight on Wegovy" benefit from strategic medication switches rather than dose increases alone. If you've been on Mounjaro and switched to Wegovy, your previous tirzepatide dose doesn't directly convert to semaglutide equivalents – you'll typically need to complete the full Wegovy escalation schedule. This restart process, whilst initially slower, often results in improved tolerability and renewed appetite suppression. Some patients find that Wegovy's once-weekly injection timing fits better with their lifestyle than daily medications, leading to improved adherence and better results.
The cost savings from switching to EverydayMeds can also reduce treatment stress, which itself may support better weight loss outcomes. Financial pressure around expensive medications can lead to dose skipping or treatment gaps – our competitive pricing eliminates these concerns. Additionally, our pharmacy stocks both Wegovy and alternatives, enabling seamless switches if your prescriber recommends trying different GLP-1 medications. This flexibility ensures you can optimise both clinical outcomes and costs without changing pharmacy providers.
Start Your Wegovy Switch Today with Confirmed Savings
Ready to address your "why am I not losing weight on Wegovy" concerns through a cost-effective switch to EverydayMeds? Begin with our 3-minute clinical assessment at https://everydaymeds.co.uk/collections/weight-loss where you can specify your current medication and dosing history. New customers automatically qualify for discount code FIRST40, whilst existing patients can use DOSE25 for continued savings on their prescription-only medicine. Our clinical team will review your switch request within 3 working days, with express 24-hour review available for urgent transitions. Once approved, your Wegovy pens arrive via next-day delivery in temperature-controlled packaging, ensuring optimal medication quality. Take control of both your weight management results and prescription costs today – your successful switch to affordable, effective Wegovy treatment starts with one simple online assessment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
